Gender differences in pulmonary disease

Mount Sinai Journal of Medicine

Volumn 70, Issue 4, 2003, Pages 215-224

  Caracta, Cynthia F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiestrogens; Asthma; Cigarette smoking; COPD; Epidemiology; Estrogens; Lung cancer; Mycobacteria; Sex hormones; Women

Indexed keywords

ANTIESTROGEN; GASTRIN RELEASING PEPTIDE; GONADORELIN AGONIST; PROGESTERONE; SEX HORMONE; TAMOXIFEN;

ASTHMA; CARCINOGENESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CULTURAL FACTOR; ECONOMIC ASPECT; FEMALE; HISTOPATHOLOGY; HUMAN; INCIDENCE; LUNG CANCER; LUNG DISEASE; LYMPHANGIOLEIOMYOMATOSIS; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OVARIECTOMY; PATHOGENESIS; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SOCIAL ASPECT; TUBERCULOSIS; CULTURAL ANTHROPOLOGY; RISK FACTOR; SOCIOECONOMICS; WOMEN'S HEALTH;

CULTURE; FEMALE; HUMANS; INCIDENCE; LUNG DISEASES; MALE; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; WOMEN'S HEALTH;

EID: 0142061174     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Guidelines for the Management of Asthma. National asthma educational project. Expert panel report. U.S. Dept. of Health and Human Services. 1991. Publication 91-3042.
2. Redline S, Gold D. Challenges in interpreting gender differences in asthma. Am J Respir Crit Care Med 1994; 150(5 Pt 1):1219-1221.
3. Bjornson CL, Mitchell I. Gender differences in asthma in childhood and adolescence. J Gender Specific Med 2000; 3(8):57-61.
4. Becklake MR, Kauffman F. Gender differences in airway behaviour over the human life span. Thorax 1999; 54:1119-1138.
5. Paoletti P, Carrozzi L, Viegi G, et al. Distribution of bronchial responsiveness in a general population: effect of sex, age, smoking, and level of pulmonary function. Am J Respir Crit Care Med 1995; 151:1779-1777.
6. Prescott E, Lange P, Vestbo J. Effect of gender on hospital admissions for asthma and prevalence of self-reported asthma: a prospective study based on a sample of the general population. The Copenhagen City Heart Study Group. Thorax 1997; 52(3):287-289.
7. Gustafsson PM, Kjellman B. Asthma from childhood to adulthood: course and outcome of lung function. Respir Med 2000; 94:466-474.
8. Kjellman B, Gustafsson PM. Asthma from childhood to adulthood: asthma severity, allergies, sensitization, living conditions, gender influence and social consequences. Respir Med 2000; 94:454-465.
9. Fagan JK, Scheff PA, Hryhorczuk D, et al. Prevalence of asthma and other allergic diseases in an adolescent population: association with gender and race. Ann Allergy Asthma Immunol 20001; 86(2):177-184.
10. Trawick DR, Holm C, Wirth J. Influence of gender on rates of hospitalization, hospital course, and hypercapnea in high-risk patients admitted for asthma: a 10-year retrospective study at Yale-New Haven Hospital. Chest 2001; 1:115-119.
11. Osborne ML, Vollmer WM, Linton KL, Buist AS. Characteristics of patients with asthma within a large HMO. Am J Respir Crit Care Med 1998; 157:123-128.
12. Hanley SP. Asthma variation with menstruation. Br J Dis Chest 1981; 75:306-308.
13. Gibbs CJ, Coutts II, Lock R, et al. Premenstrual exacerbation of asthma. Thorax 1984; 39:833-836.
14. Eliasson O, Scherzer HH, DeGraff AC, Jr. Morbidity in asthma in relation to the menstrual cycle. J Allergy Clin Immunol 1986; 77:87-94.
15. Perrin B, Bousquet J, Michel FB, et al. Severe premenstrual asthma. Lancet 1988; 833-834.
16. Pauli BD, Reid RL, Munt PW, et al. Influence of the menstrual cycle on airway function in asthmatic and normal subjects. Am Rev Respir Dis 1989; 140:358-362.
17. Balzano G, Fuschillo S, Melillo G, Bonini S. Asthma and sex hormones. Allergy 2001; 56:13-20.
18. Tan KS, Thomson NC. Review: asthma in pregnancy. Am J Med 2000; 109:727-733.
19. Nelson-Piercy C. Asthma in pregnancy. Thorax 2001; 56:325-328.
20. Juniper EF, Kline RS, Roberts FE, et al. Airway responsiveness to methacholine during the natural menstrual cycle and the effect of oral contraceptives. Am Rev Respir Dis 1987; 135:1039-1042.
21. Tan KS. Premenstrual asthma: epidemiology, pathogenesis, and treatment. Drugs 2001; 6(14):2079-2086.
22. Tan SK, McFarlane LC, Lipworth BJ. Paradoxical down-regulation and desensitization of β2- adrenoreceptors by exogenous progesterone in female asthmatics. Chest 1997; 111:847-851.
23. Tan KS, McFarlane LC, Lipworth BJ. Loss of normal cyclical β2-adrenoreceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax 1997; 52:608-611.
24. Tan KS, McFarlane LC, Lipworth BJ. β2-adrenoreceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pill. Chest 1998; 113:278-282.
25. Chandler MH, Schuldheisz S, Phillips BA, Muse KN. Premenstrual asthma: the effect of estrogen on symptoms, pulmonary function, and beta-2-receptors. Pharmacotherapy 1997; 17(2):224-234.
26. Carlson CL, Cushman M, Enright PL, et al. Hormone replacement therapy is associated with higher FEV1 in elderly women. Am J Resp Crit Care Med 2001; 163:423 -428.
27. Lieberman D, Kopernic F, Porath G, et al. Influence of estrogen replacement therapy on airway reactivity. Respiration 1995; 62:205-208.
28. Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. Am J Respir Crit Care Med 1995; 152: 1183-1188.
29. Lange P, Parner J, Prescott E, et al. Exogenous female sex steroid hormones and risk of asthma and asthma-like symptoms: a cross sectional study of the general population. Thorax 2001; 56:613-616.
30. Viegi G, Scognamilio A, Baldacci S, et al. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration 2001; 68(1):4-19.
31. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162:2152-2158.
32. Kanner RE, Connett JE, Altose MD, et al. Gender difference in airway hyperresponsiveness in smokers with mild COPD: the Lung Health Study. Am J Respir Crit Care Med 1994; 150:956-961.
33. Prescott E, Bjerg AM, Andersen PK, et al. Gender difference in smoking effects on lung function and risk of hospitalization of COPD: results from a Danish longitudinal populational study. Eur Respir J 1997; 10(4):822-827.
34. Nilsson S, Carstensen JM, Pershagen G. Mortality among male and female smokers in Sweden: a 33-year follow-up. J Epidemiol Community Health 2001; 55:825-830.
35. Mannino DM. COPD: epidemiology, prevalence, morbidity, and mortality, and disease heterogeneity. Chest 2002; 121:121S-126S.
36. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001: 119:1691-1695.
37. Diwan VK, Thorson A. Sex, gender, and tuberculosis. Lancet 1999; 353(9157):1000-1001.
38. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2:96-104.
39. Boeree MJ, Harries AD, Godschalk P, et al. Gender differences in relation to sputum submission and smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 2000; 4(9):882-884.
40. Thorson A, Diwan VK. Gender inequalities in tuberculosis: aspects of infection, notification rates, and compliance. Curr Opin Pulm Med 2001; 7(3):165-169.
41. Cegielski JP, Goetz MB, Jacobson JM, et al. Gender differences in early suspicion of tuberculosis in hospitalized, high-risk patients during 4 epidemic years, 1987 to 1990. Infect Control Hosp Epidemiol 1997; 18(4):237-243.
42. Uplekar MW, Rangan S, Weiss MG, et al. Attention to gender issues in tuberculosis control. Int J Tuberc Lung Dis 2001; 5(3):220-224.
43. Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Tuber Lung Dis 1996; 77(5):391-400.
44. Long NH, Johansson E, Diwan VK, Winkvist A. Fear and social isolation as consequences of tuberculosis in Vietnam: a gender analysis. Health Policy 2001; 58(1):69-81.
45. Begum V, de Colombani P, Das Gupta S, et al. Tuberculosis and patient gender in Bangladesh: sex differences in diagnosis and treatment outcome. Int J Tuberc Lung Dis 2001; 5(7):604-610.
46. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321(13):863-868.
47. Kubo K, Yamazaki Y, Hachiya T, et al. Mycobacterium avium-intracellulare pulmonary infection in patients without known predisposing lung disease. Lung 1998; 176:381-391.
48. Hartman TE, Swensen SJ, Williams DE. Mycobacterium avium-intracellulare complex: evaluation with CT. Radiology 1993; 187(1):23-26.
49. Teirstein AS, Damsker B, Kirschner PA, et al. Pulmonary infection with mycobacterium avium-intracellulare: diagnosis, clinical patterns, treatment. Mt Sinai J Med 1990; 57(4):209-215.
50. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting with isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101(6):1605-1609.
51. Huang JH, Kao PN, Adi V, et al. Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease. Chest 1999; 115:1033-1040.
52. Huang JH, Hefner PJ, Adi V, et al. Analyses of the NRAMP1 and INF-γR1 genes in women with mycobacterium avium intracellulare pulmonary disease. Am J Respir Crit Care Med 1998; 157:377-381.
53. Kubo K, Yamazaki Y, Hanaoka M, et al. Analysis of HLA antigens in Mycobacterium avium-intracellulare pulmonary infection. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1368-1371.
54. Tsuyuguchi K, Suzuki K, Matsumoto E, et al. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol 2001; 123:428-434.
55. Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis 1994; 18:S218-S222.
56. Sullivan, EJ. Lymphangioleiomyomatosis: a review. Chest 1998; 114:1689-1703.
57. Berger U, Khaghani A, Pomerance A, et al. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol 1990; 93 (5):609-614.
58. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol 1989; 13(9):803-807.
59. Matsui K, Tatsuguchi A, Valencia J, et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31(10):1242-1248.
60. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 2000; 67(5):311-329.
61. Kelly J, Moss J. Lymphangioleiomyomatosis. Am J Med Sci 2001; 321(1):17-25.
62. Franceschi S, Bidoli E. The epidemiology of lung cancer. Ann Onc 1999; 10(Suppl 5):S3-S6.
63. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50(1):7-33.
64. American Cancer Society. Cancer facts and figures - 1994. Atlanta, GA: American Cancer Society; 1994. pp. 1-28.
65. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Instit 1997; 89(2):1580-1586.
66. Zang, EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Instit 1996; 88(3/4):183-192.
67. Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers: a case-control analysis by histologic type. Am J Epidemiol 1993; 138:281-293.
68. Schoenberg JB, Wilcox HB, Mason TJ, et al. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol 1989; 130:688-695.
69. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking- related risk of lung cancer. Epidemiology 1992; 3:61-64.
70. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993; 54:44-58.
71. Charloux A, Quoix E, Wolkove N, et al. The increasing incidence of lung adenocarcinoma: reality or artifact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997; 26:14-23.
72. Travis WD, Travis LB, Devessa SS. Lung cancer. Cancer 1995; 75:191-202.
73. Liu N, Spitz MR, Kemp BL, et al. Adenocarcinoma of the lung in young patients. The M.D. Anderson Experience. Cancer 2000; 88:1837-1841.
74. Morgan LC, Grayson D, Peter HE, et al. Lung cancer in New South Wales: current trends and influence of age and sex. Med J Aust 2000; 172(12):578-582.
75. Sekine I, Nagai K, Tsugane S, et al. Association between smoking and tumor progression in Japanese women with adenocarcinoma of the lung. Jpn J Cancer Res 1999; 90(2):129-135.
76. Ernster VL. Female lung cancer. Annu Rev Public Health 1996; 17:97-114.
77. U.S. Department of Health and Human Services 1994. Preventing tobacco use among young people: a report of the Surgeon General. Atlanta GA: US DHHS, Public Health Service, CDC, National Center of Chronic Diseases and Preventive Health Promotions.
78. Henschke CI, McCauley DI, Yanjekevitz DF, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999; 354(9173):99-105.
79. Ouellette D, Desbiens G, Edmond, C, Beauchamp G. Lung cancer in women compared with men: stage, treatment, and survival. Ann Thor Surg 1998; 66:1140-1144.
80. Ferguson MK, Wang J, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000; 69:245-250.
81. Bouchardy C, Fioretta G, De Perrot M, et al. Determinants of long term survival after surgery for cancer of the lung: a population-based study. Cancer 1999; 86:2229-2237.
82. De Perrot M, Licker M, Bouchardy C, et al. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000; 119:21-26.
83. Wingo PA, Reis LAG, Grovino GA, et al. Annual report to the nation on the status of cancer 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Instit 1999; 91(8):675-690.
84. Landis S, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
85. Ryberg D, Hewer A, Phillips DH, Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 1994; 54(22):5801-5803.
86. Mollerup S, Ryberg D, Hewer A, et al. Sex differences in Lung CYP1A1 expression and DNA adduct levels among lung cancer patients. Cancer Res 1999; 59:3317-3320.
87. Tang D, Santella RM, Blackwood AM, et al. A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol Biomarkers Prev 1995; 4(4):341-346.
88. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194-1210.
89. Tang DL, Rundle A, Warburton D, et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 1998; 19(11):1949-1953.
90. Bennett WP, Alavanja MCR, Blomeke B, et al. Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women. J Natl Cancer Inst 1999; 91:2009-2014.
91. Wang YC, Lee HS, Chen SK, et al. Analysis of K-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome. J Cancer Res Clin Oncol 1998; 124(9):517-522.
92. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91(23):2031-2038.
93. Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 1996; 17(10):2201-2205.
94. Gealy R, Zhang L, Siegfried JM, et al. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999; 8(4 Pt 1):297-302.
95. Tseng JE, Rodriguez M, Ro J, et al. Gender differences in p53 mutational status in small cell lung cancer. Cancer Res 1999; 59:5666-5670.
96. Shriver SP, Bourdeau HA, Gubish CT, et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 2000; 92(1):24-33.
97. Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 1981; 77:186-195.
98. Taoili E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in women [letter]. J Natl Cancer Inst 1994; 86:869-870.
99. Moore JT, McKee DD, Slenta-Kesler K, et al. Cloning and characterization of human estrogen receptor β isoforms. Biochem Biophys Res Commun 1998; 247:75-78.
100. Yeh KH, Cheng AL. High-dose tamoxifen reverses drug resistance to cisplatin and etoposide in a patient with advanced large cell carcinoma of lung. Anticancer Res 1997; 17:1341-1344.
101. Lara PN, Gandara DR, Wurz GT, et al. High-dose toremifine as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol 1998; 42:504-508.
102. Yang CH, Cheng AL, Yeh KH, et al. High dose tamoxifen plus cisplatin and etoposide can be safely administered as firstline treatment to patients with advanced, inoperable nonsmall cell lung carcinoma. Favorable response rates and survival times were obtained. Cancer 1999; 86:415-420.
103. Chen YM, Perng RP, Yang KY, et al. A phase II trial of tamoxifen, ifosfamide, epirubicin, and cisplatin combination chemotherapy for inoperable non-small-cell lung cancer. Am J Clin Oncol 2000; 23 (1):13-17.